NATALIE A WORKMAN
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CHEYENNE, WY NPI 1598096182
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology WY PFIZER INC. All categories
General Payments — all program years on this page
$5,139.60
- Category: General Payments
- Program years: PY2018–2024
- Record count: 265
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $868.03 across 40 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $852.07 | 39 |
| Education | $15.96 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $90.32 | 5 |
| Daiichi Sankyo Inc. | $70.66 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $55.39 | 3 |
| E.R. Squibb & Sons, L.L.C. | $52.99 | 2 |
| Celgene Corporation | $44.68 | 1 |
| Lilly USA, LLC | $44.19 | 2 |
| Merck Sharp & Dohme Corporation | $41.45 | 2 |
| Regeneron Healthcare Solutions, Inc. | $34.32 | 2 |
| Exelixis Inc. | $33.72 | 1 |
| SOBI, INC | $31.98 | 1 |
| Janssen Biotech, Inc. | $31.50 | 1 |
| Genentech USA, Inc. | $30.52 | 1 |
| Karyopharm Therapeutics Inc. | $30.14 | 1 |
| Sumitomo Pharma America, Inc. | $26.06 | 1 |
| ABBVIE INC. | $24.26 | 1 |
| Astellas Pharma US Inc | $23.13 | 1 |
| Incyte Corporation | $21.65 | 1 |
| JAZZ PHARMACEUTICALS INC. | $21.45 | 1 |
| Genmab U.S., Inc. | $21.14 | 1 |
| Acerta Pharma LLC | $19.58 | 1 |
| Deciphera Pharmaceuticals Inc. | $19.47 | 1 |
| TAIHO ONCOLOGY, INC. | $18.84 | 1 |
| Apellis Pharmaceuticals, Inc. | $18.73 | 1 |
| Gilead Sciences, Inc. | $18.40 | 1 |
| GENZYME CORPORATION | $15.49 | 1 |
| EMD Serono, Inc. | $14.20 | 1 |
| SpringWorks Therapeutics, Inc. | $13.77 | 1 |
By program year
Records — PY2024 (40)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.